摘要
目的探讨银胶菊内酯(PTN)对脑缺血/再灌注(I/R)损伤的神经保护作用及可能机制。方法将培养的大鼠肾上腺嗜铬细胞瘤细胞系PC12细胞分为对照组、氧-糖剥夺-再灌注(OGD/R)组及PTN预处理组(1、5、10和20μmol/L,各组n=3)。CCK-8法检测细胞活力;酶活性检测试剂盒检测caspase-3、过氧化氢(H2O2)酶、超氧化物歧化酶(SOD)和谷胱甘肽过氧化物酶(GPx)的活性及乳酸脱氢酶(LDH)、活性氧(ROS);Western blot检测Bcl-2、Bax、p-Akt/Akt和p-GSK-3β/GSK-3β蛋白表达。结果与对照组相比,OGD/R组PC12细胞活力、LDH和ROS含量、Bcl-2表达水平、Akt和GSK-3β的磷酸化水平及H2O2酶、SOD和GPx的活性均明显下降(P<0.05);ROS含量、Bax-1表达量和caspase-3活性均明显升高(P<0.05);与OGD/R组相比,PTN预处理能显著缓解以上变化(P<0.05)。结论 PTN可以作为一种潜在的治疗脑I/R损伤的药物。
Objective To explore the neuroprotective effects of parthenolide( PTN) against ischemia/reperfusion( I/R) induced injuries and the underlying mechanisms. Methods PC12 cells were cultured,and divided into culture group,the oxygen-glucose deprivation and reperfusion( OGD/R) group,and PTN group( 1,5,10 and20 μmol/L,n = 3 in each group). CCK-8 assay was used to detect the cell viability. The activity of caspase-3,catalase,superoxide dismutase( SOD),glutathione peroxidase( GPx) the level of lactic dehydrogenase( LDH) and reactive oxygen spices( ROS) were determined. The protein expression of Bcl-2,Bax,p-Akt/Akt and p-GSK-3β/GSK-3β were detected using western blot. Results Compared with control group,the PC12 cells viability,the activity of catalase,SOD and GPx,and the level of LDH,ROS,Bcl-2,and phosphorylation of Akt and GSK-3β significantly decreased in the OGD/R group( P〈0. 05),with increased level of ROS,Bax-1 expression and caspase-3 activity( P〈0. 05). But PTN treatment may significantly alleviate these changes in PC12 cells,compared with OGD/R group( P〈0. 05). Conclusions PTN is a potential therapeutic drug for the cerebral I/R injury.
作者
张军峰
徐曦
徐仓宝
张一博
房智超
郝佳晖
赵朝华
ZHANG Jun-feng;XU Xi;XU Cang-bao;ZHANG Yi-bo;FANG Zhi-chao;HAOJia-hui;ZHAO Zhao-hua(Shaanxi Key Laboratory of Ischemic Cardiovascular Disease;Dept.of Human Anatomy,Xi'an Medical University,Xi'an 710021,China)
出处
《基础医学与临床》
CSCD
2018年第9期1286-1291,共6页
Basic and Clinical Medicine
基金
陕西省科技厅项目(2018JM7066)
陕西省缺血性心血管疾病重点实验室开放基金项目(2017ZDKF01)
陕西省大学生创新训练项目(G201711840002
G201711840006)
西安医学院国科金培育基金(2017GJFY25)
西安医学院配套基金项目(2016PT06)
陕西省优势学科建设经费([2014]3-1001)
陕西省教育厅科研项目(16JK1645)